A putative ubiquitin conjugating enzyme known as UBE2Q2 was previously identified in a microarray screen for mitotic regulatory proteins. UBE2Q2 is very similar to another human protein, UBE2Q1 and orthologs from other higher eukaryotic species. In these studies, we demonstrate that UBE2Q2 can covalently bind ubiquitin on the active site cysteine in vitro and show that inhibition of this protein in vivo causes an early mitotic arrest and increased cytotoxicity when cells are treated with microtubule inhibiting agents (MIAs). Changes in cell cycle progression and viability are not observed in the absence of MIA treatment, indicating that UBE2Q2 is involved in the response to MIAs rather than performing a more general function in mitosis. Inhibition of the UBE2Q2 protein causes cells to undergo a prolonged prophase arrest suggesting that UBE2Q2 normally functions to antagonize an early mitotic checkpoint. Furthermore, UBE2Q2 inhibition sensitizes cells to the cytotoxic effects of MIAs through caspase-mediated apoptosis that is correlated with PARP-1 cleavage. These data provide insights into the cellular response to MIAs and demonstrate that inhibition of UBE2Q2 protein function may be useful in the treatment of malignancies.
Introduction
A microarray study identified several components of the ubiquitin-proteasome system as mitotic regulatory proteins (Crawford and Piwnica-Worms, 2001 ). Ubiquitinmediated protein degradation is known to play a pivotal role in regulation of diverse cellular processes including both normal cell cycle regulation (reviewed in Pray et al., 2002; Vodermaier, 2004) and cell cycle checkpoint function (Scolnick and Halazonetis, 2000; Lew and Burke, 2003; Matsusaka and Pines, 2004; Zhang et al., 2005) . Ubiquitin conjugating enzymes (or E2s) perform an intermediate step in the enzymatic cascade and provide some of the specificity for the process of target protein ubiquitination through their interactions with specific ubiquitin ligases (or E3s) (reviewed in Weissman, 2001) .
Many malignancies are treated with drugs that inhibit microtubule function, thereby causing mitotic arrest and cell apoptosis. These microtubule inhibiting agents (MIAs) include two distinct classes of drugs: vinca alkaloids (such as vincristine and vinorelbine) and taxanes (such as paclitaxel and docetaxel). The mitotic arrest induced by MIAs is mediated by at least two distinct checkpoints. The checkpoint with forkhead and ring (CHFR) checkpoint (also referred to as the mitotic stress checkpoint and the antephase checkpoint) causes a prophase arrest with transient chromatin decondensation (Rieder and Cole, 2000; Scolnick and Halazonetis, 2000; Matsusaka and Pines, 2004) . This checkpoint is inactivated in many human tumors and cell lines by loss of expression of the ubiquitin ligase CHFR (Mizuno et al., 2002; Corn et al., 2003; Toyota et al., 2003; Matsusaka and Pines, 2004) . Later in mitosis, spindle assembly checkpoint activation can arrest cells in prometaphase and metaphase, blocking progression to anaphase (Rieder et al., 1994; Gorbsky, 2001; Musacchio and Hardwick, 2002) . These two checkpoints are essential for preventing aneuploidy and the development of malignancies, as shown in animal models (Baker et al., 2005) .
MIAs exert their chemotherapeutic effect by induction of apoptosis, although the mechanism leading to cell death is poorly understood. A clear correlation between mitotic arrest and induction of apoptosis by MIAs suggest a functional link between the two processes (Bhalla, 2003; Mollinedo and Gajate, 2003) , although some data suggest that the two events may be separable (Huang et al., 2004) .
One G2/M-specific gene identified in our microarray screen (Crawford and Piwnica-Worms, 2001 ) was a previously uncharacterized ubiquitin conjugating enzyme now referred to as UBE2Q2 (also LOC92912 and UBCi) (Melner et al., 2004; Seghatoleslam et al., 2006) . In these studies, we have demonstrated that this protein likely functions as an E2 and that it plays an important role in the cellular response to microtubule inhibiting agents by regulating an early mitotic checkpoint.
Results
Cell cycle phase-specific expression of UBE2Q2 The EST (AA476260) representing UBE2Q2 in our microarray study (Crawford and Piwnica-Worms, 2001 ) is now referred to as UBE2Q2 or LOC92912 in GenBank and recent publications (Melner et al., 2006; Seghatoleslam et al., 2006) . UBE2Q2 is very similar to another human protein known as UBE2Q1 (or NICE-5) and a C. elegans protein known as UBC-25 (Schulze et al., 2003) . A schematic of these proteins show that UBE2Q1 and UBE2Q2 share the same domain organization with an N-terminal RWD domain and a C-terminal UBC domain ( Figure 1a ) as was reported previously for UBE2Q2 (Seghatoleslam et al., 2006) . These proteins are likely to function as ubiquitin E2s by virtue of the very highly conserved C-terminal UBC domain (Schulze et al., 2003; Melner et al., 2004; Melner et al., 2006) , an E2 catalytic domain with a conserved cysteine residue that is required for activity (Aristarkhov et al., 1996) . We have demonstrated that UBE2Q2 can covalently bind ubiquitin at this active site cysteine (Supplementary Figure S1) , strongly supporting the proposal that this protein functions as an E2. Others have conducted similar experiments suggesting that UBE2Q2 functions in this capacity (Melner et al., 2006) .
To examine the UBE2Q2 gene expression pattern throughout the cell cycle, HeLa cells were synchronized in G1 phase using a double-thymidine block and release. Synchronous cell cycle progression (Figure 1b ) was accompanied by cell cycle phase specific expression of the UBE2Q2 mRNA (Figure 1c ). The UBE2Q2 mRNA is barely detectable in G1 synchronized cells, but accumulates and reaches a maximum expression at 9 h after release, coincident with the time when the highest fraction of cells are completing mitosis and entering G1. The mRNA levels return to baseline by 15 h after release. We also analysed expression of UBE2Q2 mRNA in human tissues and cancer cell lines using multiple tissue northern blots and found ubiquitous expression of UBE2Q2 mRNA in all cell lines and tissues (data not shown).
Dominant-negative UBE2Q2 potentiates the mitotic arrest induced by MIAs
The catalytic function of ubiquitin-conjugating enzymes is dependent on a conserved cysteine residue. Dominantnegative inhibitors with mutations of this residue have been used to analyse the function of many E2s (Banerjee et al., 1995; Tashiro et al., 1997; Townsley et al., 1997; Pati et al., 1999; Gu and Roizman, 2003; Li et al., 2003) . We used site-directed mutagenesis to create such a mutant molecule, UBE2Q2 (C304A) , referred to as DN-UBE2Q2-FLAG. We stably transfected HeLa cells and isolated clones that expressed wild type (wt) or DN-UBE2Q2-FLAG (Figure 2a ). The small difference in migration for the wild type clone is a result of the presence of a nine amino-acid StrepII tag (Skerra and Schmidt, 1999) . The stably transfected wt-and DN-UBE2Q2 cells displayed no overt phenotype under normal growth conditions. Since UBE2Q2 is expressed in a G2/M-specific manner, a possible role in mitotic regulation was examined. We initially analysed one clone expressing UBE2Q2 inactivation increases the cytotoxicity of MIAs S Banerjee et al dominant-negative UBE2Q2 (DN-UBE2Q2 clone 1) in several assays. We synchronized these cells using a double-thymidine block. Upon release, the fraction of cells in each cell cycle phase was determined using flow cytometry. DN-UBE2Q2 expression did not appear to alter the rate of mitotic entry or exit, since there was no To further explore the role of UBE2Q2 in mitosis, we analysed the effect of DN-UBE2Q2-FLAG expression on cell cycle progression in cells treated with a dose of vincristine similar to that achieved in patients receiving a continuous infusion of the medication (Pinkerton et al., 1988) . Control and DN-UBE2Q2-expressing cells were synchronized using a double-thymidine block and then released into medium containing 3 nM vincristine. Cells were harvested for analysis by flow cytometry at intervals thereafter. Control cells accumulate in mitosis after initiation of vincristine treatment, but escape from this arrest after twelve hours ( Figure 2d ) and progress into G1 (Figure 2e) , similar to what has been reported previously (Kung et al., 1990; Rieder and Palazzo, 1992) . In contrast, DN-UBE2Q2-expressing cells continue to accumulate in mitosis ( Figure 2d ) and fail to progress into the G1-phase of the cell cycle ( Figure 2e ). In control cells, the peak fraction of mitotic cells occurs at about the same time in vincristine treated and untreated cells (Figure 2b and d respectively), but the mitotic fraction is much greater in cells treated with this MIA (B40% in Figure 2b versus B5% in Figure 2d ). In other experiments, a small delay in mitosis is observed in cells expressing wild type UBE2Q2, but the cells complete mitosis and progress into G1. This brief delay (Supplementary Figure S3) is very different than the irreversible cell cycle arrest in cells expressing DN-UBE2Q2. Several independent clones expressing DN-UBE2Q2 display the same phenotype, indicating that the aberrant response to vincristine is a result of DN-UBE2Q2 expression rather than an artifact of clonality (Supplementary Figure S4) . To confirm this phenotype is a result of UBE2Q2 inactivation, we demonstrated that UBE2Q2 knockdown by siRNA causes a very similar effect, inducing a mitotic arrest in response to vincristine treatment (Supplementary Figure S7D) .
To better define the mitotic arrest potentiated by UBE2Q2 inactivation, cells were treated with low-dose vincristine for 16 h, and then stained with DAPI before analysis by fluorescence microscopy. Under these conditions, control cells are almost exclusively in interphase, while cells expressing DN-UBE2Q2 arrest in prophase with condensed chromatin (Figure 2f 
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To characterize further the vincristine-induced mitotic arrest that is potentiated by UBE2Q2 inactivation, we used a higher dose of vincristine to increase the fraction of arrested cells. Mitotic cells were collected by shakeoff and then re-plated in the absence of drugs to determine their ability to complete mitosis and resume cell division. While almost all control cells and cells expressing wild type UBE2Q2 adhered to the dish within 6 h, almost no DN-UBE2Q2-expressing cells re-adhered to the dish, even after 24 h. Fluorescence-activated cell sorting analysis confirmed that control and wild type UBE2Q2-expressing cells completed mitosis (Figure 3a ) and entered G1 (Figure 3b ). On the other hand, the fraction of mitotic DN-UBE2Q2-expressing cells declined very slowly (Figure 3a) without a coincident rise in G1-phase cells (Figure 3b ). Microscopic analysis of these cells at the time of drug withdrawal revealed that control cells are arrested primarily in prometaphase and metaphase, consistent with an activated spindle assembly checkpoint (Figure 3c 
DN-UBE2Q2 expression enhances the cytotoxicity of MIAs
To determine if DN-UBE2Q2 expression sensitized cells to vincristine-induced cytotoxicity, we used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and trypan blue exclusion assays. Non-transfected HeLa cells and HeLa cells stably transfected with either empty vector, wild type UBE2Q2, or DN-UBE2Q2 (DN-UBE2Q2) were treated with escalating doses of vincristine ( Figure 4a ) and cell survival was measured using the MTT assay. The first clone analysed in this way, DN-UBE2Q2-FLAG clone 1, was approximately 10-fold more sensitive to vincristine-induced cell death. Three independent clones expressing DN-UBE2Q2 displayed a similar sensitization to this drug (Figure 4b ). Inhibition of UBE2Q2 by siRNA also greatly increases the sensitivity of cells to vincristine, as shown by trypan blue (Supplementary Figure S7E -F) and colony forming assays (Supplementary Figure S7G ).
To determine whether these effects were specific to microtubule inhibition, we performed similar experiments using other chemotherapeutic agents including other MIAs (nocodazole and paclitaxel) and DNA damaging agents (doxorubicin and etoposide). We found that DN-UBE2Q2 expression sensitized cells to both paclitaxel (Figure 4c ) and nocodazole (not shown), but not to doxorubicin (Figure 4d ) or etoposide (not shown). Using a trypan blue exclusion assay, we confirmed that vincristine caused an increase in cell death in DN-UBE2Q2 expressing cells rather than just a decrease in the rate of proliferation (Figure 4e ). DN-UBE2Q2 expression did not alter the rate of cell death after doxorubicin treatment (Figure 4f ).
Increased sensitivity to MIA is owing to induction of apoptosis
The increased cytotoxicity to MIAs in cells expressing DN-UBE2Q2 could be a result of either a potentiation of the typical apoptotic response to MIAs or activation of an alternative mechanism that also leads to cell death. To distinguish these two possibilities, we examined whether DN-UBE2Q2-expressing cells undergo apoptosis at low doses of vincristine. Control and DN-UBE2Q2 cells were treated with vincristine (3 nM) for the indicated times and cells were stained with Annexin-V and propidium iodide. A tremendous increase in apoptotic cells was observed at both early (19.2 versus 7.6% at 24 h) and late (67.7 versus 34.9% at 48 h) time points (Figure 5a and b) , indicating that the increased cell death in DN-UBE2Q2 cells occurs through apoptosis. These data clearly show that vincristine-induced cell death in DN-UBE2Q2 is correlated with Annexin-V positivity, a well-established indicator of apoptosis. However, Annexin-V positivity appears to overestimate the impact on cell proliferation and survival as measured by the MTT assay (Figure 4a and b) and trypan blue exclusion assay (Figure 4e) .
Induction of apoptosis was further confirmed by two additional methods; cleavage of the 112-kD poly(ADPribose) polymerase-1 (PARP-1) into a 89-kDa species (Koh et al., 2005) and observation of characteristic apoptotic morphological changes in cell nuclei (Pallardy et al., 1999) . After low-dose vincristine treatment, cells expressing DN-UBE2Q2 had much more cleaved PARP-1 than control cells (Figure 5c ), while those expressing wild type UBE2Q2 had somewhat less cleaved PARP-1. Similarly, cells expressing DN-UBE2Q2 showed nuclear fragmentation and condensation characteristic of apoptosis while control and wild-type UBE2Q2 cells did not (Figure 5d and data not shown). To characterize further the vincristine-induced apoptosis in cells with inactivated UBE2Q2, we performed a series of experiments using a caspase inhibitor. These studies demonstrate that vincristine-induced death, but not the mitotic arrest, is dependent on caspase activity (Supplementary Figure S6A-C) .
Discussion
In these experiments, we have demonstrated that UBE2Q2 plays an important role in the cellular response to microtubule inhibition. Inactivation of UBE2Q2 causes cells to undergo a prophase arrest and apoptosis after treatment with MIAs. This effect is very specific, since UBE2Q2 inhibition does not alter cell cycle progression in unperturbed cells nor does it alter the toxicity of DNA damaging agents. Since UBE2Q2 inhibition causes a mitotic arrest only in the setting of microtubule inhibition, it is altering the function of a mitotic checkpoint rather than perturbing normal mitotic regulation.
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The arrest induced by UBE2Q2 depletion is similar to the CHFR checkpoint, but distinct from the spindle assembly checkpoint that occurs at a later stage of mitosis. Since HeLa cells lack a functional CHFR checkpoint (Matsusaka and Pines, 2004) , it is possible that UBE2Q2 inhibition is restoring this checkpoint. However, it is also possible that it is activating a distinct early mitotic checkpoint. Although the mitotic arrest induced by normal CHFR expression and by UBE2Q2-inhibition are both activated by microtubule stress and occur in prophase, the two may differ in other respects. First, the CHFR-mediated prophase arrest causes chromatin decondensation in an apparent return from prophase to interphase (Rieder and Cole, 2000; Matsusaka and Pines, 2004) , which has led some to refer to this as the antephase checkpoint. Thus far, we have clones that were stably transfected with either empty vector, wild-type UBE2Q2, or DN-UBE2Q2 were compared for sensitivity to vincristine. Cells were treated in triplicate with escalating doses of vincristine for 72 h and assessed by MTT assay for cell killing. All control cells have similar sensitivity to vincristine, while the DN-UBE2Q2-expressing cells are greatly sensitized to vincristine relative to controls with Po0.01 at all doses. (b) Three independently established DN-UBE2Q2 clones were compared for sensitivity to escalating doses of vincristine using the MTT assay. Drug treatments and MTT assays were performed in triplicate. Each DN-UBE2Q2-expressing clone has statistically increased sensitivity to vincristine (Pp0.01) at 1, 3 and 10 nM vincristine. (c and d) Stably transfected DN-UBE2Q2 cells were compared in triplicate with control cells for sensitivity to paclitaxel and doxorubicin using the MTT assay. DN-UBE2Q2 expression sensitizes cells to paclitaxel (c) (Po0.05 at 30, 100 and 300 mM), but does not alter sensitivity to doxorubicin (d). (e and f) Stably transfected cells were treated with low-dose vincristine or doxorubicin for 4 days. Cells were harvested daily in triplicate and analysed for cell killing using a trypan-blue exclusion assay. DN-UBE2Q2 expression increases the cell death induced by vincristine (Po0.01 at 2, 3 and 4 days) (e), but does not alter the cell killing induced by doxorubicin (f).
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S Banerjee et al not observed chromatin decondensation in HeLa cells with inactivated UBE2Q2, although the nuclear architecture during the prophase arrest is clearly abnormal. A second difference is observed in the checkpoint duration. The CHFR-mediated checkpoint has been reported to be transient, even with protracted MIA treatment (Scolnick and Halazonetis, 2000) . In contrast, UBE2Q2-inhibited cells appear to have a nearly permanent prophase arrest. Whether UBE2Q2 and CHFR function in the same or distinct signaling pathways, it is clear that they are performing opposite functions in checkpoint signaling. CHFR activates cell cycle arrest while UBE2Q2 antagonizes cell cycle arrest. These data are consistent with a model wherein UBE2Q2 functions to allow resumption of mitosis after a prophase checkpoint is activated by other protein(s) (Figure 6 ). Our data do not definitively distinguish between the possibility that this is one in the same as the CHFR checkpoint (Figure 6a ) or a distinct prophase checkpoint (Figure 6b ), although the former possibility is more likely. Since UBE2Q2 antagonizes checkpoint function, its overexpression might be expected to promote the development of aneuploidy and/or malignancy. Interestingly, UBE2Q2 has been shown to be overexpressed in some malignancies (Seghatoleslam et al., 2006) . The increased cytotoxicity of MIAs in cells after UBE2Q2 inhibition is likely a consequence of the protracted arrest since the two processes appear to be linked. We have demonstrated that MIA-induced cell death in UBE2Q2-inhibited cells is a result of apoptosis, and is correlated with PARP-1 cleavage. However, the cells are greatly sensitized to these drugs, making UBE2Q2 an attractive potential target in the treatment of malignancies. Inhibition of UBE2Q2 with a small molecule inhibitor or with RNA interference would be expected to sensitize cancer cells to treatment with vinca alkaloids and taxanes, drugs that are useful in a broad variety of human malignancies. Since these proteins do not appear to play an important role outside of mitosis, one might expect that their inhibition would confer little additional toxicity for non-dividing cells than that, which would be observed with vincristine alone.
Using similar experimental approaches, at least two other E2s have been shown to play a role in mitosis. Control and DN-UBE2Q2-expressing cells were treated with 3 nM vincristine for 48 h. The medium was aspirated and the cells were fixed with 4% buffered paraformaldehyde and then stained with DAPI. Cells were analysed by fluorescence microscopy. Fluorescent images were converted to Grayscale for publication using Adobe Photoshop.
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Expression of dominant-negative UbcH10 causes a metaphase arrest by inactivation of APC/C function (Townsley et al., 1997) . Similarly, dominant-negative Cdc34 also causes a metaphase arrest in at least one experimental model (Liu et al., 2006) . However, to our knowledge, UBE2Q2 is unique, since no other E2 that has been shown to directly influence checkpoint function. Identification of the E3 that functions in concert with UBE2Q2 and the targets of the ubiquitination reaction will give great insight into this early mitotic checkpoint.
Materials and methods
Cell culture, synchronization and drug treatment HeLa cells were obtained from ATCC and propagated using standard growth conditions. Transfections, cell synchronization and drug treatments were performed according to established protocols, as detailed in the Supplementary information (Chen and Okayama, 1987; Crawford and Piwnica-Worms, 2001 ).
Construction of expression plasmids and recombinant protein expression A full length UBE2Q2 cDNA was cloned into pET15b (Novagen, Darmstadt, Germany) and 3XFLAG-CMV10 (Sigma-Aldrich, St Louis, MO, USA) for bacterial and mammalian expression. A point mutation (C304A) was introduced using the QuickChange Mutagenesis kit (Stratagene, La Jolla, CA, USA). Primers used for cloning are listed in Supplementary Information. 6His-tagged recombinant wildtype and mutant UBE2Q2 were prepared in E. coli BL21(DE3) and purified using Ni-NTA agarose (Qiagen, Valencia, CA, USA) according to standard methodology.
siRNA transfection siRNA duplexes directed against UBE2Q2 from Dharmacon (Lafayette, CO, USA) were: Q2-1 (5 0 -GUAUGGAACUUCU CACAAAUU), Q2-2 (5 0 -UUAUAUGACUGGCAUGUUA UU), Q2-3 (5 0 -GCCCAACAAUCCUAUAAUUUU) and Q2-4(5 0 -AAGGAUAACUUUCCAUUUGUU). The luciferase control duplex sequence was: 5 0 -AACUUA CGCUGAGUACUUCGA.
Immunoblotting and northern blotting
Immunoblotting and northern blotting were performed using standard methodology and as described previously (Crawford and Piwnica-Worms, 2001 ). Details are provided in the Supplementary Information.
Cell proliferation and survival assays Cell survival and propagation after different drug treatments was assessed using the MTT assay (Li et al., 2004) . Cell death after drug treatment was determined by the trypan blue exclusion and colony forming assays. Details of our application of these standard methods are provided in the Supplementary Information.
Flow cytometry
To determine cell cycle phase, cultured cells were analysed by flow cytometry to determine DNA content and phosphorylation status of serine-10 on histone H3 (Xu et al., 2001) . Our application of standard methodologies is detailed in the Supplementary Information.
Immunofluorescence microscopy Cultured cells were fixed in buffered formaldehyde, stained with DAPI, and analysed by microscopy using an Olympus AX70 fluorescence microscope equipped with a Zeiss Axiocam camera (Carl Zeiss, Oberkochem, Germany). a Figure 6 A model of UBE2Q2 function in prophase checkpoint function. Two possible roles for UBE2Q2 in mitotic checkpoint function are shown. (a) In the first model, microtubule inhibition leads to activation of the CHFR checkpoint and delayed activation of UBE2Q2. CHFR mediates a prophase arrest, but UBE2Q2 relieves this arrest, leading to resumption of mitotic progression. In this model, UBE2Q2 is predicted to function downstream of CHFR in the signaling pathway since inactivation of the CHFR checkpoint in HeLa cells is a result of absence of CHFR protein expression. (b) In a second model, microtubule inhibition leads to activation of two checkpoints including both the CHFR checkpoint and a distinct prophase checkpoint. Delayed activation of UBE2Q2 would be predicted to relieve the second, previously undescribed, prophase checkpoint that functions independently of CHFR.
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